康乃德生物 CNTB 深 沪
等待开盘 08-29 09:30:00 美东时间
1.76
-0.020
-1.12%
华盛通- 最 高1.83
- 今 开1.78
- 成交量 13.09万股
- 最 低 1.755
- 昨 收 1.78
- 总市值 9807.02万
- 52周最高 2.86
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 0.51
- 委 比 85.29%
- 总股本 5572.17万
- 历史最高 29.274
- 量 比 1.43
- 振 幅 4.21%
- 历史最低 0.51
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Connect Biopharma collaborates with the Jovante Woods Foundation to expand asthma education across the U.S., raising awareness about acute asthma attacks. The partnership marks 15 years since Jovante Woods' death from an asthma attack. The Foundation, established by Ickey and Chandra Woods, focuses on prevention and treatment education. Connect, developing a novel asthma treatment, supports the initiative with a video story and community events d...
08-14 12:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Connect Biopharma GAAP EPS of -$0.23
Connect Biopharma press release (NASDAQ:CNTB): Q2 GAAP EPS of -$0.23. More on Connect Biopharma Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financi...
08-14 00:38
Connect Biopharma Hldgs Q2 EPS $(0.23) Misses $(0.22) Estimate, Sales $48.000K Down From $24.116M YoY
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 185.19 percent decrease over earnings of $0.27 per
08-13 21:14
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported significant progress in Q2 2025, advancing its Phase 2 Seabreeze STAT studies for asthma and COPD, showcasing positive data supporting rademikibart’s potential. The company also submitted a new drug application in China via licensee Simcere and terminated its ADR program, listing directly on Nasdaq to enhance institutional visibility. Additionally, Jim Schoeneck, an industry veteran, was appointed to the Board, bringing...
08-13 13:00
中泰证券：创新药企分化加剧 重点推荐先声药业等创新药标杆企业
近期以来，医药板块行情呈现多元化趋势：从创新药单主线驱动，逐步延伸至业绩反转、脑机接口及AI制药等新兴领域，同时创新药内部结构性分化加剧，市场风格呈现高低切...
08-12 10:02
Connect Biopharma Expands Board, Appoints New Director
Connect Biopharma Holdings ( ($CNTB) ) just unveiled an update. On July 22, 202...
07-22 21:28
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 44.6% to $446.6 du...
07-22 20:07
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Connect Biopharma Holdings Limited has expanded its Board of Directors to seven members, appointing Jim Schoeneck as a new director. Schoeneck, a seasoned biotech leader with over 40 years of experience, brings expertise in drug development and commercialization, expected to accelerate progress for the company's lead drug candidate, rademikibart. Rademikibart is a next-generation antibody targeting IL-4Rα, currently in Phase 2 trials for treating...
07-22 13:00
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
Connect Biopharma宣布终止存托协议，计划将存托凭证转换为普通股并于2025年9月2日在纳斯达克直接上市。此举旨在提高机构可见度，减少费用，并拓展投资者基础。公司专注于哮喘和慢性阻塞性肺病的治疗，其药物rademikibart正在推进II期临床试验。
07-21 13:00
